Aquilab joins the Coexya group

We are pleased to inform you that AQUILAB has joined the COEXYA group, an independent digital leader in integration and software development in #healthcare.

The merger will take advantage of their complementary nature and enable us to create multi-centric clinical studies. COEXYA will use its ConSore solution to create cohorts of patients, while AQUILAB will use ONCO PLACE to manage clinical studies.

For David Gibon, AQUILAB’s chief executive :
“The merger with COEXYA will enable us to strengthen our expertise in data and AI so as to step up our development in predictive medicine. AQUILAB and COEXYA have customers in common and share the same values. By leveraging these synergies, we will be able to propose new solutions and provide better treatment to people suffering from cancer.”